Lantheus inks deal to market Definity in China

Lantheus Medical Imaging has formed a strategic relationship with Beijing Double-Crane Pharmaceuticals for the distribution and supply of Definity in China.

The boards of directors of both Lantheus and Beijing Double-Crane have approved a 15-year agreement for exclusive distribution and supply of Definity, an ultrasound contrast agent for use in in echocardiograms. Lantheus and Double-Crane plan to fully execute the agreement in the next several weeks in China.

Under the terms of the agreement, both parties will collaborate on confirmatory clinical trials to commercialize Definity in China for use in cardiac disease.

The agreement also provides Double-Crane the right of first negotiation to manufacture Definity in China upon the achievement of certain sales levels. In addition, Double-Crane has the right to negotiate the manufacture of Definity in China in the event Lantheus chooses to seek a Chinese manufacturing partner for the product.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.